Nektar Therapeutics

NASDAQ:NKTR

1.42 (USD) • At close July 12, 2024
Bedrijfsnaam Nektar Therapeutics
Symbool NKTR
Munteenheid USD
Prijs 1.42
Beurswaarde 261,308,400
Dividendpercentage 0%
52-weken bereik 0.41 - 1.93
Industrie Biotechnology
Sector Healthcare
CEO Mr. Howard W. Robin
Website https://www.nektar.com

An error occurred while fetching data.

Over Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder

Vergelijkbare Aandelen

Codexis, Inc. logo

Codexis, Inc.

CDXS

3.2 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

11.77 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

22.5 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.47 USD

Merus N.V. logo

Merus N.V.

MRUS

57.26 USD

Verve Therapeutics, Inc. logo

Verve Therapeutics, Inc.

VERV

6.73 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

8.72 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)